

A new Power Of Attorney is enclosed. Please direct all future correspondence to customer number 28765.

Respectfully submitted,

Date: 4/23/02



Allan A. Fanucci (Reg. No. 30,256)

WINSTON & STRAWN
200 Park Avenue
New York, New York 10166-4193

(212) 294-3311

APPENDIX A
MARKED COPY OF AMENDED CLAIM

17. A CB2 specific [antagonist] agonist comprising a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,


R₁ is (a) -R'N(R'')₂ wherein R' is C₁-C₅ straight or branched chain alkyl and each R'', which may be the same or different, is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR''' or -OC(O)R''' moiety wherein R''' is hydrogen or C₁-C₅ straight or branched chain alkyl, (b) -Q wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) -R'X wherein R' is C₁-C₅ straight or branched chain alkyl and X is halogen, (d) -R'C(O)N(R'')₂ wherein R' is a direct bond or C₁-C₅ straight or branched chain alkyl and each R'', which may be the same or different, is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR''' or -OC(O)R''' moiety wherein R''' is hydrogen or C₁-C₅ straight or branched chain alkyl, (e) -R'C(O)OR'' wherein R' is a direct bond or C₁-C₅ straight or branched chain alkyl and R'' is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR''' or -OC(O)R''' moiety wherein R''' is hydrogen or C₁-C₅ straight or branched chain alkyl, (f) -R' wherein R' is C₁-C₅ straight or branched chain alkyl, or (g) -R'OR''' wherein R' is C₁-C₅ straight or branched chain alkyl and R''' is hydrogen or C₁-C₅ alkyl;

G is hydrogen, halogen, or $-OR_2$ wherein R_2 is hydrogen or C_1-C_5 straight or branched chain alkyl optionally containing a terminal $-OR'''$, $-OC(O)R'''$, $C(O)OR'''$, or $-C(O)R''$ moiety wherein R''' is hydrogen or C_1-C_5 straight or branched chain alkyl; and R_3 is (a) C_1-C_{12} straight or branched chain alkyl, (b) $-OR'''$, in which R''' is a straight chain or branched C_2-C_9 alkyl which may be substituted at the terminal carbon atom by a phenyl group, or (c) $-(CH_2)_n OR'''$ wherein n is an integer of 1 to 7 and R''' is hydrogen or C_1-C_5 alkyl.

APPENDIX B

CURRENTLY PENDING CLAIMS

1. A pharmaceutical composition for treating or preventing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune disease, comprising as an active ingredient a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R_1 is (a) $-R'N(R'')_2$ wherein R' is C_1 - C_5 straight or branched chain alkyl and each R'' , which may be the same or different, is hydrogen or C_1 - C_5 straight or branched chain alkyl optionally containing a terminal $-OR'''$ or $-OC(O)R'''$ moiety wherein R''' is hydrogen or C_1 - C_5 straight or branched chain alkyl, (b) $-Q$ wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) $-R'X$ wherein R' is C_1 - C_5 straight or branched chain alkyl and X is halogen, (d) $-R'C(O)N(R'')_2$ wherein R' is a direct bond or C_1 - C_5 straight or branched chain alkyl and each R'' , which may be the same or different, is hydrogen or C_1 - C_5 straight or branched chain alkyl optionally containing a

terminal -OR''' or -OC(O)R''' moiety wherein R''' is hydrogen or C₁-C₅ straight or branched chain alkyl, (e) -R'C(O)OR'' wherein R' is a direct bond or C₁-C₅ straight or branched chain alkyl and R'' is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR''' or -OC(O)R''' moiety wherein R''' is hydrogen or C₁-C₅ straight or branched chain alkyl, (f) -R' wherein R' is C₁-C₅ straight or branched chain alkyl, or (g) -R'OR''' wherein R' is C₁-C₅ straight or branched chain alkyl and R''' is hydrogen or C₁-C₅ alkyl;

G is hydrogen, halogen, or -OR₂ wherein R₂ is hydrogen or C₁-C₅ straight or branched chain alkyl optionally containing a terminal -OR''', -OC(O)R''', C(O)OR''', or -C(O)R'' moiety wherein R''' is hydrogen or C₁-C₅ straight or branched chain alkyl; and

R₃ is (a) C₁-C₁₂ straight or branched chain alkyl, (b) -OR'''' in which R'''' is a straight chain or branched C₂-C₉ alkyl which may be substituted at the terminal carbon atom by a phenyl group, or (c) -(CH₂)_n OR''' wherein n is an integer of 1 to 7 and R''' is hydrogen or C₁-C₅ alkyl.

2. The compound of claim 1 wherein, R₃ is a straight chain or branched chain -C₅-C₁₂ alkyl.

3. The compound of claim 1, wherein R₃ is 1,1-dimethyl heptyl or 1,2-dimethyl heptyl.

4. The compound of claim 1, wherein R₁ is -CH₂OH, G is -OCH₃, and R₃ is 1,1-dimethyl heptyl.


5. The compound of claim 1, wherein R₁ is -CH₂OH, C(O)N(R'')₂, -C(O)OR'', -COOH, an amino acid, or a carboxamide.

6. A pharmaceutical composition for treating, preventing, or managing hypertension, inflammation, peripheral pain, gastrointestinal disorders, or autoimmune diseases comprising as an active ingredient a therapeutically effective amount of a compound of claim 1.

7. A pharmaceutical composition of claim 6 further comprising a pharmaceutically acceptable diluent or carrier.

8. The pharmaceutical composition of claim 7, wherein the diluent is an aqueous cosolvent solution comprising a pharmaceutically acceptable cosolvent, a micellar solution or emulsion prepared with natural or synthetic ionic or non-ionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions.

17. A CB2 specific agonist comprising a compound of the general formula:



having the (3S,4S) configuration, and which is essentially free of the (3R,4R) enantiomer, wherein:

A---B designates an optional double bond,

R_1 is (a) $-R'N(R'')_2$ wherein R' is C_1 - C_5 straight or branched chain alkyl and each R'' , which may be the same or different, is hydrogen or C_1 - C_5 straight or branched chain alkyl optionally containing a terminal $-OR'''$ or $-OC(O)R'''$ moiety wherein R''' is hydrogen or C_1 - C_5 straight or branched chain alkyl, (b) $-Q$ wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) $-R'X$ wherein R' is C_1 - C_5 straight or branched chain alkyl and X is halogen, (d) $-R'C(O)N(R'')_2$ wherein R' is a direct bond or C_1 - C_5 straight or branched chain alkyl and each R'' , which may be the same or different, is hydrogen or C_1 - C_5 straight or branched chain alkyl optionally containing a terminal $-OR'''$ or $-OC(O)R'''$ moiety wherein R''' is hydrogen or C_1 - C_5 straight or branched chain alkyl, (e) $-R'C(O)OR''$ wherein R' is a direct bond or C_1 - C_5 straight or branched chain alkyl and R'' is hydrogen or C_1 - C_5 straight or branched chain alkyl optionally containing a terminal $-OR'''$ or $-OC(O)R'''$ moiety wherein R''' is hydrogen or C_1 - C_5 straight or branched chain alkyl, (f) $-R'$ wherein R' is C_1 - C_5 straight or branched chain alkyl, or (g) $-R'OR'''$ wherein R' is C_1 - C_5 straight or branched chain alkyl and R''' is hydrogen or C_1 - C_5 alkyl;

G is hydrogen, halogen, or $-OR_2$ wherein R_2 is hydrogen or C_1 - C_5 straight or branched chain alkyl optionally containing a terminal $-OR'''$, $-OC(O)R'''$, $C(O)OR'''$, or $-C(O)R''$ moiety wherein R''' is hydrogen or C_1 - C_5 straight or branched chain alkyl; and

R_3 is (a) C_1 - C_{12} straight or branched chain alkyl, (b) $-OR''''$, in which R'''' is a straight chain or branched C_2 - C_9 alkyl which may be substituted at the terminal carbon atom by a phenyl group, or (c) $-(CH_2)_n OR'''$ wherein n is an integer of 1 to 7 and R''' is hydrogen or C_1 - C_5 alkyl.